AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 202 min read$ANIX

Titterton Lewis H jr purchased $42K of ANIX

Titterton Lewis H jr purchased 12,000 shares of Anixa Biosciences Inc (ANIX) at $3.47 on 2026-07-20.

Original reporting
SEC EDGAR · Titterton Lewis H jr
Published Jul 20, 2026, 10:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 20, 2026, 10:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ANIX
Bullish
medium confidence
Mentioned
$ANIX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ANIXBullishLow
01

Why it matters

A new insider open-market purchase was disclosed at a specific price and share count, which can modestly influence sentiment but does not, by itself, change fundamentals.

02

Market read

Traders may monitor for follow-on insider activity, but the filing alone is unlikely to drive a major repricing without additional operational catalysts.

03

What to watch

The filing does not state intent, timing constraints, or whether the purchase is part of a broader pattern; traders should compare with prior Form 4 activity and overall volume/liquidity.

Relevance 4/10Novelty 5/10Timing: Filed on 2026-07-20, same day as the reported purchase date.

Background

This is an SEC Form 4 insider transaction for Anixa Biosciences, reported by a director.

Company-level read

Ticker impact

$ANIXBullishMedium confidence
Context

Director Titterton Lewis H jr filed a Form 4 open-market purchase of 12,000 ANIX shares at $3.4700 on 2026-07-20.

Expected impact

Likely limited near-term impact; may slightly support sentiment if traders treat insider buying as a signal.

Evidence & confidence

Form 4 confirms a new transaction today, yet it does not include guidance, trial results, contracts, or other company-specific fundamentals that typically drive repricing.

Market effects

Sector

Minimal, as this is a single-company insider transaction without sector-wide information.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider buys can be routine or driven by diversification, liquidity needs, or non-informational factors, especially without a 10b5-1 plan.

Key entities

  • issuer
    Anixa Biosciences Inc

    Subject of the Form 4 insider transaction, ticker ANIX.

  • insider
    Titterton Lewis H jr

    Director who reported an open-market purchase of 12,000 shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ANIX insider trading history →

Related articles

OCT 6
$ANIXMedAI 8/10

H.C. Wainwright reiterates Buy on Anixa stock, $6 target on trial data

H.C. Wainwright reiterated a Buy rating and $6 target on Anixa Biosciences (ANIX) after positive trial data. The stock trades at $2.95, with analysts' targets ranging from $6 to $14. The company reported stable disease in a patient from its Phase 1 trial of lira-cel for ovarian cancer. ANIX holds a strong financial position with a current ratio of 8.54 and more cash than debt. The firm expects further trial updates soon.

investing.com2 min
OCT 5
$ANIXMed

Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences reported that a patient in its Phase 1 trial for ovarian cancer CAR-T therapy showed stable disease 3 months post-treatment. No dose-limiting toxicities were observed. The trial, conducted at Moffitt Cancer Center, aims to assess safety and preliminary efficacy of lira-cel, a novel CAR-T therapy targeting FSHR. Multiple patients have survived over a year, with one exceeding two years.

prnewswire.com2 min
OCT 1
$ANIXMedAI 8/10

Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences (NASDAQ: ANIX) announced the second patient has been treated in the fifth cohort of its Phase 1 clinical trial for recurrent ovarian cancer. The trial, conducted at Moffitt Cancer Center, evaluates a novel FSHR-targeted CAR-T therapy. Patients in the fifth cohort receive 1×10⁷ CAR-positive cells/kg following lymphodepletion. No dose-limiting toxicities have been observed, and multiple patients have survived over a year, with one surpassing two years.

prnewswire.com2 min
SEP 11
$ANIXMedAI 8/10

RedChip Companies, Inc.: Anixa Biosciences and Nexalin Technology Interviews to Air Nationally on the RedChip Small Stocks, Big Money Show on CNBC and Bloomberg TV

RedChip Companies will air interviews with Anixa Biosciences (NASDAQ:ANIX) and Nexalin Technology (NASDAQ:NXL) on Bloomberg TV and CNBC. Anixa is developing a breast cancer vaccine, while Nexalin focuses on neurostimulation for mental health. Both companies are preparing for key trials and commercialization efforts.

finanznachrichten.de2 min
OCT 7
$LWAYLow

Divisadero Street Capital Management, LP (Zolezzi William) purchased $2.2M of LWAY (indirect holdings)

Divisadero Street Capital Management, LP purchased 103,684 indirectly-held shares of Lifeway Foods, Inc. (LWAY) at an average of $20.92 ($20.80–$21.09, $2.17M total) across 3 trades over 2026-10-02 to 2026-10-06. Filed jointly with Divisadero Street Partners GP, LLC (10% owner), Zolezzi William (10% owner), Divisadero Street Partners, L.P. (10% owner) and Divisadero Street Capital, LLC (10% owner).

SEC EDGAR1 min